Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT06966921
Completed Not applicable

Cranial Electrotherapy Stimulation in Chronic Psychiatric Patients

NCT06966921 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Liu Hsing Yu
Phase
Not applicable
Started
2025-04-20
Last updated
2026-10-01

Condition(s) studied

SleepDepression Disorders

Investigational drug(s) / intervention(s)

CES

CES: Currently, most CES intervention studies are applied to the general public, and a few studies focus on athletic performance. There are no related studies on residents of psychiatric nursing homes, nor are there any research designs for improving cognitive impairment. Therefore, this study explores the use of CES programs to improve the cognition, anxiety, depression, and other conditions of residents of psychiatric care homes, with the goal of improving their quality of life.

Study summary

This randomized, gender-stratified study evaluated cranial electrotherapy stimulation (CES) in residents with chronic psychiatric disorders living in a psychiatric nursing home. Seventy participants were randomly assigned to early CES or delayed CES (35 per group). The early-CES group received 40-minute sessions five days a week for 12 weeks (60 sessions). Participants were assessed at baseline, at 12 weeks, and 3 and 6 months after the 12-week period. The delayed-CES group began CES after the week-12 assessment. The study examined changes over time under these two treatment schedules.

Eligibility

Sex
ALL
Min age
20 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * 1\. Chronic mental illness patients, 2. Mini-Mental State Examination (MMSE) ≥ 16 points, 3. Education level is junior high school graduates or above, 4. Appropriate oral expression ability, 5. Those who can complete the research consent form, 6. Those who are willing to participate in this study Exclusion Criteria: * 1\. Those with obvious risk of violence or suicide 2. People with cognitive impairment who have been diagnosed with mental retardation or autism

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tsaotun Psychiatric Center, MOHW Nantou City Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06966921 on ClinicalTrials.gov ↗ ← All trials in Taiwan